Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions
Simon Arsène, Claire Couty, Igor Faddeenkov, Natacha Go, Solène Granjeon-Noriot, Daniel J. Smit, Riad Kahoul, Ben Illigens, Jean‐Pierre Boissel, Aude Chevalier, Lorenz Lehr, Christian Pasquali, Alexander Kulesza
Abstract
Respiratory disease trials are profoundly affected by non-pharmaceutical interventions (NPIs) against COVID-19 because they perturb existing regular patterns of all seasonal viral epidemics. To address trial design with such uncertainty, we developed an epidemiological model of respiratory tract infection (RTI) coupled to a mechanistic description of viral RTI episodes. We explored the impact of reduced viral transmission (mimicking NPIs) using a virtual population and in silico trials for the bacterial lysate OM-85 as prophylaxis for RTI. Ratio-based efficacy metrics are only impacted under strict lockdown whereas absolute benefit already is with intermediate NPIs (eg. mask-wearing). Consequently, despite NPI, trials may meet their relative efficacy endpoints (provided recruitment hurdles can be overcome) but are difficult to assess with respect to clinical relevance. These results advocate to report a variety of metrics for benefit assessment, to use adaptive trial design and adapted statistical analyses. They also question eligibility criteria misaligned with the actual disease burden.